Author:
Joris Sofie,Pieters Thierry,Sibille Anne,Bustin Fréderique,Jacqmin Laurence,Kalantari Hassan Rezaei,Surmont Veerle,Goeminne Jean-Charles,Clinckart Frederic,Pat Karin,Demey Wim,Deschepper Koen,Lambrechts Marc,Holbrechts Stephane,Schallier Denis,Decoster Lore
Subject
Geriatrics and Gerontology,Oncology
Reference25 articles.
1. Safety, activity and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012
2. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial;Rizvi;Lancet Oncol,2015
3. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer;Brahmer;N Engl J Med,2015
4. Nivolumab versus docetaxel in advanced non squamous non-small cell lung cancer;Borghaei;N Engl J Med,2015
5. SEER Cancer Statistics Factsheets: lung and bronchus cancer. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/statfacts/html/lungb.html. [accessed 19 February 2019].
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献